TNFSF4 (tumor necrosis factor receptor ligand superfamily, member 4), OX40L, CD134L
|Molecule Type||Antigen Expression||Molecular Weight|
Min / Max
|Non-lineage Restricted Molecule|
Type 2 glycoprotein
|34 / 34|
CD252 is expressed on antigen presentation cells including B cells, dendritic cells, mast cells and endothelium. Expression is also on cardiac monocytes and human T cell leukemia virus type 1 cells. There is also expression in the human spleen, thymus and heart.
|MOLECULAR FAMILY NAME: Belongs to the tumor necrosis factor superfamily.|
CD252 is a single-pass type-2 183 aa glycoprotein. It contains a 133-residue extracellular domain which contains 4 potential N-glycosylation sites, a transmembrane domain and a cytoplasmic domain.
The molecular weight that was predicted to be 21 kDa and was observed to be 34 kDa.
POST-TRANSCRIPTIONAL MODIFICATION: No information.
POST-TRANSLATIONAL MODIFICATION: No information.
|LIGANDS AND MOLECULE ASSOCIATED WITH CD252|
CD252 is a ligand for CD134 (TNFRSF4/OX40).
|The protein encoded by CD252 is a cytokine that belongs to the TNF ligand family. CD252, a membrane-expressed cytokine, can act as costimulator through interaction with its ligand on T cells. CD252 interaction co-stimulates T cell activation, proliferation and cytokine production. This cytokine is a ligand for receptor CD134. In surface Ig- and CD40 (OX40)- stimulated B cells, this cytokine along with CD70 has been shown to provide CD28-independent costimulatory signals to T cells. CD40 on T cells can adhere to CD252 on vascular endothelium. |
BIOCHEMICAL ACTIVITY: No information.
DISEASE RELEVANCE AND FUNCTION OF CD252 IN INTACT ANIMAL
CD252 is expressed in psoriatic skin and airways muscle and may be a therapeutic target in psoriasis and asthma. The gene is polymorphic, but so far no associations have been reported with disease severity.
PROTEINS AND DNA ELEMENTS WHICH REGULATE TRANSCRIPTION OF CD252: No information.
SUBSTRATES: No information.
ENZYMES WHICH MODIFY CD252: No information.
For further information see Kotani, A. et al (2002) Immunol. Lett. 84: 1-7.
Database accession numbers
Revised June 25, 2008